Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lianxia Ningxin Granules (连夏宁心颗粒) is a traditional Chinese medicine (TCM) hospital preparation developed and used in China, primarily as an in-hospital formulation. It is designed for cardiovascular indications, with clinical research focused on its effects in conditions such as myocardial infarction and potentially other heart-related diseases. The granule formulation is based on the "Lianxia Ningxin" prescription, which typically combines multiple herbal ingredients to exert synergistic effects such as improving blood circulation, protecting cardiac tissue, and modulating inflammation or oxidative stress. The exact mechanism of action depends on the specific herbal components but generally involves multi-target modulation typical of TCM formulas[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lianxia Ningxin Granules.